Page 2 - Read Online
P. 2
Topic: Targeting DNA
Topoisomerases - Past and
Future
Dr. van Waardenburg obtained his Ph.D. in Medical Oncology from
the University of Groningen, the Netherlands, in the group of Drs.
Nanno Mulder and Elisabeth de Vries. His first post-doctoral fellowship
was at The Netherlands Cancer Institute, with Dr. Jan Schellens and
collaborator Dr. Jaap Brouwer (University of Leiden, the Netherlands).
His second post-doctoral fellowship was at St. Jude Children’s Hospital,
Dr. Robert C.A.M. van Memphis, TN, in the group of Dr. Mary-Ann Bjornsti. He subsequently
Waardenburg joined the University of Alabama at Birmingham (UAB) and is currently
an Associate Professor in the Department of Pharmacology and
Department of Pharmacology and Toxicology, Toxicology. He also is the Director of the UAB Graduate Biomedical
University of Alabama at Birmingham, Sciences, Pathobiology, Pharmacology and Physiology (P3) theme.
Birmingham, AL, USA.
Dr. Gmeiner received a B.A. from the University of Chicago and
Ph.D. from the University of Utah. He went on to become an Alberta
Heritage Medical Research Fellow prior to becoming Assistant and then
Associate Professor with tenure at the Eppley/UNMC Cancer Institute
and visiting Professor at the University of California at San Francisco.
He is now Professor of Cancer Biology at Wake Forest School of
Medicine with appointments in the Department of Physiology and
Pharmacology, Molecular Medicine, and the Wake Forest/VirginiaTech
Dr. William H. Gmeiner biomedical graduate sciences graduate program.
Department of Cancer Biology, Wake Forest Dr. Gmeiner is an expert in fluoropyrimidine (FP) chemotherapy
University School of Medicine, Winston- for treatment of colorectal cancer (CRC) and other malignancies. He
Salem, NC, USA. is the inventor of fluoropyrimidine polymer technology for cancer
treatment with more than 10 issued patents. FP polymers are being
studied at the Nanotechnology Characterization Laboratory, part
of the U.S. National Cancer Institute (ncl.cancer.gov), and at leading
academic medical centers. Dr. Gmeiner has received NIH R01, U01,
R21 awards from NIH-NCI and grants from the U.S. Congressionally
Directed Medical Research Program, the North Carolina Biotechnology
Center and other agencies. Dr. Gmeiner regularly serves on NIH study
sections and reviews grants for other leading agencies. He has published
approximately 100 peer-reviewed publications. His research focuses on
both cancer biology and fluoropyrimidine chemistry and emphasizes
translational science. Among the important findings in Dr. Gmeiner’s
research career is that FPs target DNA topoisomerase 1 in addition to
thymidylate synthase.
